Theory of Drug Development (Chapman & Hall/CRC Biostatistics Series)
Language: English
Published by Chapman and Hall/CRC, 2013
- Hardcover
- Used

Seller: Michael Knight, Bookseller, Forest Grove, OR, U.S.A.Michael Knight, Bookseller
AbeBooks seller since February 24, 2023
Condition: Used - Good
US$ 110.61
Quantity: 1 available
Add to basketItem description from seller
Hardcover issued without dust-jacket. Front fly-leaf has been removed. Otherwise, clean and solid.
Seller Inventory # mon0000017548
- Title
- Theory of Drug Development (Chapman & Hall/CRC Biostatistics Series)
- Author
- Holmgren, Eric B.
- Publisher
- Chapman and Hall/CRC
- Publication year
- 2013
- Condition
- Good
- Binding
- hardcover
- Language
- English
- ISBN 10
- 1466507462
- ISBN 13
- 9781466507463
- Series
- Book 38 of 155: Chapman & Hall/CRC Biostatistics
Theory of Drug Development presents a formal quantitative framework for understanding drug development that goes beyond simply describing the properties of the statistics in individual studies. It examines the drug development process from the perspectives of drug companies and regulatory agencies.
By quantifying various ideas underlying drug development, the book shows how to systematically address problems, such as:
- Sizing a phase 2 trial and choosing the range of p-values that will trigger a follow-up phase 3 trial
- Deciding whether a drug should receive marketing approval based on its phase 2/3 development program and recent experience with other drugs in the same clinical area
- Determining the impact of adaptive designs on the quality of drugs that receive marketing approval
- Designing a phase 3 pivotal study that permits the data-driven adjustment of the treatment effect estimate
- Knowing when enough information has been gathered to show that a drug improves the survival time for the whole patient population
Drawing on his extensive work as a statistician in the pharmaceutical industry, the author focuses on the efficient development of drugs and the quantification of evidence in drug development. He provides a rationale for underpowered phase 2 trials based on the notion of efficiency, which leads to the identification of an admissible family of phase 2 designs. He also develops a framework for evaluating the strength of evidence generated by clinical trials. This approach is based on the ratio of power to type 1 error and transcends typical Bayesian and frequentist statistical analyses.
"Synopsis" may belong to another edition of this title.
About the Author
Eric B. Holmgren is a consultant and statistical scientist. He previously worked at Genentech and Hoechst Roussel Pharmaceuticals. He received a Ph.D. in mathematical statistics from Stanford University.
"About the title" may belong to another edition of this title.
Michael Knight, Bookseller
Forest Grove, OR, U.S.A.
AbeBooks seller since February 24, 2023
Shipping rates within U.S.A.
| Item | 5 to 14 business days | 3 to 6 business days |
|---|---|---|
| First item | US$ 3.00 | US$ 9.20 |
Payment methods
Specialty
Primarily used non-fictionSeller's business information
Michael Knight, Bookseller
OR, U.S.A.
Terms of sale
We guarantee the condition of every book as it's described
on the Abebooks web
sites. If you're dissatisfied with your purchase (Incorrect
Book/Not as
Described/Damaged) or if the order hasn't arrived, you're
eligible for a refund
within 30 days of the estimated delivery date. If you've
changed your mind about a
book that you've ordered, please use the Ask bookseller a
question link to contact
us and we'll respond within 2 business days.
Shipping terms
Shipping costs are based on books weighing 2.2 LB, or 1 KG. If your book order is heavy or oversized, we may contact you to let you know extra shipping is required.